Contents

Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure (MERCURY)

November 1, 2019

Clinical trial

Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.

Asrani S, Robin AL, Serle JB, Lewis RA, Usner DW, Kopczynski CC, Heah T.

Am J Ophthalmol. 2019 Nov;207:248-257.
Full text | Metrics.

Main finding: Netarsudil/latanoprost fixed dose combination (FDC) was superior to netarsudil or latanoprost in lowering intraocular pressure over 3 months.

 

  • Purpose: To compare the ocular hypotensive efficacy and safety of a fixed-dose combination of the Rho kinase inhibitor netarsudil and latanoprost vs monotherapy with netarsudil or latanoprost in Ocular Hypertension/Open-angle glaucoma
  • Study type: Randomized controlled trial
  • Condition: Open angle glaucoma, Ocular Hypertension

Participants: OHT or OAG, unmedicated IOP 21-35 mmHg

 

  • n=718 (MERCURY-1)

 

Intervention:

 

  • Group 1: Netarsudil 0.02%
  • Group 2: Latanoprost 0.005%
  • Group 3: Netarsudil/latanoprost fixed dose combination (FDC)

Netarsudil/latanoprost FDC was superior to netarsudil or latanoprost, lowering IOP by an additional 2.2-3.3 mmHg versus netarsudil and an additional 1.5-2.4 mmHg versus latanoprost.

 

The commonest adverse effect was conjunctival hyperaemia.

 

 

Study Netarsudil Latanoprost Netarsudil/latanoprost FDC
Mean diurnal IOP ≤ 15 mmHg (proportion) MERCURY-1 15.8% 18.3% 42.1%
MERCURY-2 22.7% 24.7% 43.5%
Incidence of Conjunctival hyperaemia MERCURY-1 and 2 41-42.7% 14-22.3% 53.4-54.5%

September 1, 2019

Clinical trial

Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.

Walters TR, Ahmed IIK, Lewis RA, Usner DW, Lopez J, Kopczynski CC, Heah T.

Ophthalmol Glaucoma. 2019 Sep-Oct;2(5):280-289.
Full text | Metrics.

Main finding: Netarsudil/latanoprost fixed dose combination (FDC) was superior to netarsudil or latanoprost in lowering intraocular pressure over 3 months.

 

  • Purpose: To compare the ocular hypotensive efficacy and safety of a fixed-dose combination of the Rho kinase inhibitor netarsudil and latanoprost vs monotherapy with netarsudil or latanoprost in Ocular Hypertension/Open-angle glaucoma
  • Study type: Randomized controlled trial
  • Condition: Open angle glaucoma, Ocular Hypertension

Participants: OHT or OAG, unmedicated IOP 21-35 mmHg

 

  • n=750 (MERCURY-2)

 

Intervention:

 

  • Group 1: Netarsudil 0.02%
  • Group 2: Latanoprost 0.005%
  • Group 3: Netarsudil/latanoprost fixed dose combination (FDC)

Netarsudil/latanoprost FDC was superior to netarsudil or latanoprost, lowering IOP by an additional 2.2-3.3 mmHg versus netarsudil and an additional 1.5-2.4 mmHg versus latanoprost.

 

The commonest adverse effect was conjunctival hyperaemia.

 

 

Study Netarsudil Latanoprost Netarsudil/latanoprost FDC
Mean diurnal IOP ≤ 15 mmHg (proportion) MERCURY-1 15.8% 18.3% 42.1%
MERCURY-2 22.7% 24.7% 43.5%
Incidence of Conjunctival hyperaemia MERCURY-1 and 2 41-42.7% 14-22.3% 53.4-54.5%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed